Physician profile
Satish Agadi
NPI 1275724585
$8,353.67
in general payments reported to CMS, 2019-2025
10 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Neurodevelopmental Disabilities (Pediatrics) provider received nationally (typical 2025 total: $136).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,423 · 2021: $165 · 2022: $372 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aquestive Therapeutics, INC. | $7,221.31 | 2019 | |
| Ucb, INC. | $254.45 | 2021-2025 | |
| Sk Life Science, INC. | $218.87 | 2022-2025 | |
| Abbvie INC. | $190.53 | 2022 | |
| Eisai INC. | $125.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $116.00 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $115.71 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.08 | 2019 | |
| Allergan, INC. | $19.10 | 2022 | |
| Biomarin Pharmaceutical INC. | $15.62 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Agadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.